ARVN
Price:
$7.67
Market Cap:
$494.88M
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Fur...[Read more]
Industry
Biotechnology
IPO Date
2018-09-27
Stock Exchange
NASDAQ
Ticker
ARVN
According to Arvinas, Inc.’s latest financial reports and current stock price. The company's current ROE is -44.39%. This represents a change of 280.25% compared to the average of -11.67% of the last 4 quarters.
The mean historical ROE of Arvinas, Inc. over the last ten years is -1010.51%. The current -44.39% ROE has changed -95.61% with respect to the historical average. Over the past ten years (40 quarters), ARVN's ROE was at its highest in in the March 2025 quarter at 12.56%. The ROE was at its lowest in in the December 2017 quarter at -1922.98%.
Average
-1010.51%
Median
-33.21%
Minimum
-9781.27%
Maximum
-18.58%
Discovering the peaks and valleys of Arvinas, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 16.28%
Maximum Annual ROE = -18.58%
Minimum Annual Increase = -99.69%
Minimum Annual ROE = -9781.27%
| Year | ROE | Change |
|---|---|---|
| 2025 | -18.63% | -47.40% |
| 2024 | -35.41% | -36.37% |
| 2023 | -55.65% | 11.28% |
| 2022 | -50.01% | 104.67% |
| 2021 | -24.43% | 31.53% |
| 2020 | -18.58% | -40.09% |
| 2019 | -31.01% | 2.16% |
| 2018 | -30.35% | -99.69% |
| 2017 | -9781.27% | 16.28% |
The current ROE of Arvinas, Inc. (ARVN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-36.56%
5-year avg
-36.83%
10-year avg
-1010.51%
Arvinas, Inc.’s ROE is greater than Valneva SE (-106.22%), greater than ArriVent BioPharma, Inc. Common Stock (-48.98%), greater than Day One Biopharmaceuticals, Inc. (-23.43%), greater than Astria Therapeutics, Inc. (-45.01%), greater than Replimune Group, Inc. (-102.69%), less than MeiraGTx Holdings plc (474.91%), greater than Iovance Biotherapeutics, Inc. (-50.17%), greater than Geron Corporation (-28.90%), greater than Ginkgo Bioworks Holdings, Inc. (-57.31%), greater than Erasca, Inc. (-77.01%),
| Company | ROE | Market cap |
|---|---|---|
| -106.22% | $510.15M | |
| -48.98% | $1.48B | |
| -23.43% | $2.22B | |
| -45.01% | $718.13M | |
| -102.69% | $841.41M | |
| 474.91% | $1.05B | |
| -50.17% | $1.40B | |
| -28.90% | $808.32M | |
| -57.31% | $599.03M | |
| -77.01% | $4.25B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arvinas, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Arvinas, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Arvinas, Inc.'s ROE?
How is the ROE calculated for Arvinas, Inc. (ARVN)?
What is the highest ROE for Arvinas, Inc. (ARVN)?
What is the 3-year average ROE for Arvinas, Inc. (ARVN)?
What is the 5-year average ROE for Arvinas, Inc. (ARVN)?
How does the current ROE for Arvinas, Inc. (ARVN) compare to its historical average?